文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

中药治疗咳嗽变异性哮喘:双盲随机对照试验研究方案

Chinese herbal medicine for the treatment of cough variant asthma: a study protocol for a double-blind randomized controlled trial.
PubMed 文献 · Trials · 2019-01-03

该研究为双盲随机安慰剂对照试验,计划纳入60例18-70岁咳嗽变异性哮喘患者,1:1随机分入中药颗粒剂组或安慰剂组,两组均以沙美特罗/氟替卡松为基础治疗12周,干预3个月后随访6个月,主要结局为咳嗽视觉模拟评分,旨在评估中药联合抗炎药物的安全性、有效性及长期疗效。

要点

  • 中药颗粒剂(4.9g 每日两次)联合沙美特罗/氟替卡松治疗咳嗽变异性哮喘。
  • 主要结局为咳嗽视觉模拟评分(CVAS),随访6个月评估长期疗效。
  • 样本量60例,年龄18-70岁,双盲安慰剂对照设计。

核心结论

  • 该试验旨在评估中药联合抗炎药物治疗咳嗽变异性哮喘的安全性、有效性及长期疗效。

研究设计与样本

  • 双盲随机安慰剂对照试验,计划纳入60例18-70岁咳嗽变异性哮喘患者,1:1随机分组。
  • 干预3个月后随访6个月,两组均以沙美特罗/氟替卡松联合治疗12周为基础治疗。

关键数值与推荐

  • 试验组口服中药颗粒剂4.9g每日两次,对照组给予匹配安慰剂。
  • 主要结局为咳嗽视觉模拟评分(CVAS),次要结局包括生活质量、症状复发率、肺功能及血液检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cough variant asthma (CVA) is one of the leading causes of chronic coughing. The main treatment is currently anti-inflammatory medication. However, the coughing may return or be aggravated and lung function may deteriorate once the anti-inflammatory treatment is stopped. The effect of Chinese herbal medicine (CHM) on chronic coughing is remarkable, but high-quality evidence supporting its effectiveness is still lacking. This trial aims to evaluate the safety and efficacy, especially the long-term efficacy, of CHM plus anti-inflammatory medications for the treatment of CVA. METHODS/DESIGN: A randomized placebo-controlled double-blind trial will be conducted. It will consist of a 3-month intervention followed by a 6-month follow-up period. The target sample size is 60 patients with CVA who are between 18 and 70 years old. The eligible subjects will be allocated randomly into the experimental or control group in a ratio of 1:1. Patients in the experimental group will take CHM granules (4.9 g twice daily), while patients in the control group will be given a matched placebo. An administration of salmeterol/fluticasone propionate combination for 12 weeks will be the basic therapy for the two groups. The primary outcome is the cough visual analog scales (CVAS). The secondary outcomes include quality of life, rate of symptom relapse, lung function, and blood tests. A safety assessment will also be performed during the trial. DISCUSSION: The evidence gathered by the trial will be a valuable addition to informing treatment options for patients with CVA. TRIAL REGISTRATION: http://www.chictr.org.cn , ID: ChiCTR-IOR-16009148. Registered on 3 September 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Fan RR, Wen ZH, Wang DW, et al. Chinese herbal medicine for the treatment of cough variant asthma: a study protocol for a double-blind randomized controlled trial. Trials. 2019. PMID: 30606237. doi:10.1186/s13063-018-3073-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。